CDKN2A and melanoma: As an oncogene, cyclin-dependent kinase inhibitor 2A (CDKN2A) can encode p16 and p14, often expressed as homozygous deletions in a variety of cancers, such as oral squamous cell carcinoma and melanoma 48,49.